Arkansas is rushing to execute seven death row inmates in 11 days this month before the US states lethal drugs used in injections expire, the media reported.
Arkansas officials blame the hurried execution schedule on the drug shortage, which has sent states scrambling for replacement chemicals and, in some cases, has caused them to contemplate other methods of execution, The Washington Post reported on Friday.
These executions would be the first in Arkansas in 12 years.
Governor Asa Hutchinson has admitted to feeling uneasy about being caught between needing to schedule them and the looming expiration of the state's stock of midazolam, a controversial sedative that will be one of three drugs used in the lethal injections.
"It's not my choice," Hutchinson told the media on Friday.
"I would love to have those extended over a period of multiple months and years, but that's not the circumstances that I find myself in."
The state's midazolam supply is set to expire at the end of April, according to officials.
"It is uncertain as to whether another drug can be obtained," the Governor added.
The seven inmates still facing execution all were convicted of capital murder. They all received their sentences by the year 2000.
Drug manufacturers are required by law to put an expiration date on drugs in the US, and after that date they cannot guarantee the drug's effectiveness or safety, reports The Washington Post.
Arkansas acquired its midazolam in 2015, according to state documents.
The drug prompted controversy after it was used in a bungled execution in Oklahoma and in lethal injections that were prolonged and included inmates gasping for breath in Ohio, Arizona and in Alabama.
Lethal injection remains the US' primary method of execution, but due to the shortage, states have also been looking to other methods.
Utah, Tennessee and Oklahoma added or broadened their abilities to use a firing squad, electric chair or nitrogen gas.
--IANS
ksk/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
